The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Lipotoxicity associated with insulin resistance is central to nonalcoholic steatohepatitis (NASH) pathogenesis. To date, only weight loss fully reverses NASH pathology, but mixed peroxisome proliferator–activated receptor‐alpha/delta (PPAR‐α/δ) agonists show some efficacy. Seladelpar (MBX‐8025), a selective PPAR‐δ agonist, improves atherogenic dyslipidemia. We therefore used this agent to test whether selective PPAR‐δ activation can reverse hepatic lipotoxicity and NASH in an obese, dyslipidemic, and diabetic mouse model. From weaning, female Alms1 mutant (foz/foz) mice and wild‐type littermates were fed an atherogenic diet for 16 weeks; groups (n = 8‐12) were then randomized to receive MBX‐8025 (10 mg/kg) or vehicle (1% methylcellulose) by gavage for 8 weeks. Despite minimally altering body weight, MBX‐8025 normalized hyperglycemia, hyperinsulinemia, and glucose disposal in foz/foz mice. Serum alanine aminotransferase ranged 300‐600 U/L in vehicle‐treated foz/foz mice; MBX‐8025 reduced alanine aminotransferase by 50%. In addition, MBX‐8025 normalized serum lipids and hepatic levels of free cholesterol and other lipotoxic lipids that were increased in vehicle‐treated foz/foz versus wild‐type mice. This abolished hepatocyte ballooning and apoptosis, substantially reduced steatosis and liver inflammation, and improved liver fibrosis. In vehicle‐treated foz/foz mice, the mean nonalcoholic fatty liver disease activity score was 6.9, indicating NASH; MBX‐8025 reversed NASH in all foz/foz mice (nonalcoholic fatty liver disease activity score 3.13). Conclusion: Seladelpar improves insulin sensitivity and reverses dyslipidemia and hepatic storage of lipotoxic lipids to improve NASH pathology in atherogenic diet–fed obese diabetic mice. Selective PPAR‐δ agonists act independently of weight reduction, but counter lipotoxicity related to insulin resistance, thereby providing a novel therapy for NASH. (Hepatology Communications 2017;1:663–674)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 3×
“PPAR-c is the master regulator of adipogenesis and lipogenic pathways in adipocytes; the thiazolidinedione PPAR-c agonists improve peripheral and hepatic insulin sensitivity((16,18,19)) and have some efficacy in NASH((14)) but without reversal of NASH pathology.”
BackgroundChitturi, S., Abeygunasekera, S., Farrell, G. C., Holmes-Walker, J., Hui, J. M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.30692 · Cited by 1,122
Self-citationNeuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 2×
“Although NASH is a highly prevalent, serious disease, there is no currently approved drug therapy.((1,2,6,7)) While reversing consequences of metabolic disorder has been attempted to target NASH, the only highly effective strategies have been bariatric surgery and lifestyle changes; reducing body weight 10% reverses N…”
BackgroundRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis
Kakisaka, K., Cazanave, S. C., Fingas, C. D., Guicciardi, M. E., Bronk, S. F., Werneburg, N. W., Mott, J. L., & Gores, G. J. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00301.2011 · Cited by 222 · cited 1×
“FC and possibly other lipid and bile acid– related molecules have been shown to cause lipotoxicity in primary hepatocytes.((32,37)) Physical activity and weight loss improve insulin sensitivity and so correct the hepatic accumulation of lipotoxic lipids.”
BackgroundPeroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
Souza-Mello, V. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1012 · Cited by 182
Krämer, D. K., Al-Khalili, L., Guigas, B., Leng, Y., Garcia-Roves, P. M., & Krook, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702329200 · Cited by 180
Research works printed but not linked: 32
- 2012, Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis, Hepatology, 56, 943, 10.1002/hep.25772 · DOI · Paper page
- 2013, NAFLD in Asia—as common and important as in the West, Nat Rev Gastroenterol Hepatol, 10, 307, 10.1038/nrgastro.2013.34 · DOI · Paper page
- 2011, Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis, Gastroenterology, 141, 1393, 10.1053/j.gastro.2011.06.040 · DOI · Paper page
- 2012, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications, Gastroenterology, 142, 711, 10.1053/j.gastro.2012.02.003 · DOI · Paper page
- 2012, Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease, Cell Metab, 15, 665, 10.1016/j.cmet.2012.04.004 · DOI · Paper page
- 2015, Childhood adiposity trajectories and risk of nonalcoholic fatty liver disease in adolescents, J Gastroenterol Hepatol, 30, 163, 10.1111/jgh.12666 · DOI
- 2015, Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 · DOI · Paper page
- 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005 · DOI · Paper page
- 2016, Non‐alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies, Nat Rev Drug Discov, 15, 249, 10.1038/nrd.2015.3 · DOI · Paper page
- 2017, Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice, Obesity, 25, 155, 10.1002/oby.21701 · DOI · Paper page
- 2015, Current efforts and trends in the treatment of NASH, J Hepatol, 62, S65, 10.1016/j.jhep.2015.02.041 · DOI · Paper page
- 2012, A myriad of pathways to NASH, Clin Liver Dis, 16, 525, 10.1016/j.cld.2012.05.009 · DOI
- 2011, The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact, Trends Pharmacol Sci, 32, 607, 10.1016/j.tips.2011.06.006 · DOI
- 2013, Peroxisome proliferator–activated receptor delta and cardiovascular disease, Atherosclerosis, 231, 95, 10.1016/j.atherosclerosis.2013.08.027 · DOI
- 2008, Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity‐induced insulin resistance, Cell Metab, 7, 496, 10.1016/j.cmet.2008.04.003 · DOI · Paper page
- 2012, Lipid effects of peroxisome proliferator–activated receptor‐Δ agonist GW501516 in subjects with low high‐density lipoprotein cholesterol characteristics of metabolic syndrome, Arterioscler Thromb Vasc Biol, 32, 2289, 10.1161/ATVBAHA.112.247890 · DOI · Paper page
- 2011, Mechanism of action of a peroxisome proliferator–activated receptor (PPAR)‐δ agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity, J Clin Endocrinol Metab, 96, E1568, 10.1210/jc.2011-1131 · DOI
- 2014, GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes, Expert Opin Investig Drugs, 23, 1441, 10.1517/13543784.2014.954034 · DOI
- 2012, Effects of the PPAR‐δ agonist MBX‐8025 on atherogenic dyslipidemia, Atherosclerosis, 220, 470, 10.1016/j.atherosclerosis.2011.10.029 · DOI
- 2011, MBX‐8025, a novel peroxisome proliferator receptor‐δ agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin, J Clin Endocrinol Metab, 96, 2889, 10.1210/jc.2011-1061 · DOI · Paper page
- 2008, Activation of peroxisome proliferator–activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men, Diabetes, 57, 332, 10.2337/db07-1318 · DOI · Paper page
- 2013, Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome, J Hepatol, 59, 144, 10.1016/j.jhep.2013.02.024 · DOI
- 2015, Exercise improves adipose function and inflammation and ameliorates fatty liver disease in obese diabetic mice, Obesity, 23, 1845, 10.1002/oby.21170 · DOI · Paper page
- 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
- 2007, Discovery of para‐alkylthiophenoxyacetic acids as a novel series of potent and selective PPARδ agonists, Bioorg Med Chem Lett, 17, 3855, 10.1016/j.bmcl.2007.05.007 · DOI
- 2014, Hepatocyte free cholesterol lipotoxicity results from JNK1‐mediated mitochondrial injury and is HMGB1 and TLR4‐dependent, J Hepatol, 61, 1376, 10.1016/j.jhep.2014.07.024 · DOI · Paper page
- 2004, Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18, Cancer Res, 64, 1751, 10.1158/0008-5472.CAN-03-2455 · DOI · Paper page
- 2013, Desnutrin/ATGL activates PPARδ to promote mitochondrial function for insulin secretion in islet β cells, Cell Metab, 18, 883, 10.1016/j.cmet.2013.10.012 · DOI · Paper page
- 2014, Brown and white adipose tissues: intrinsic differences in gene expression and response to cold exposure in mice, Am J Physiol Endocrinol Metab, 306, E945, 10.1152/ajpendo.00473.2013 · DOI · Paper page
- 2006, Activation of PPAR‐δ in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids, Diabetologia, 49, 2713, 10.1007/s00125-006-0357-6 · DOI
- 2014, New peroxisome proliferator–activated receptor agonists: potential treatments for atherogenic dyslipidemia and non‐alcoholic fatty liver disease, Expert Opin Pharmacother, 15, 493, 10.1517/14656566.2014.876992 · DOI · Paper page
- 2008, PPAR‐β/δ agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home, Expert Opin Investig Drugs, 17, 1465, 10.1517/13543784.17.10.1465 · DOI · Paper page
Cited by
PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Wang, Y., Nakajima, T., Gonzalez, F. J., & Tanaka, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062061 · Cited by 540
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.031 · Cited by 332
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Farrell, G., Schattenberg, J. M., Leclercq, I., Yeh, M. M., Goldin, R., Teoh, N., & Schuppan, D. (2019) · Hepatology · doi:10.1002/hep.30333 · Cited by 313
“2), with typical NAS scores of 6-8.(11,24,25) The extent of fibrosis (generally stage 1-2) depends on strain and feeding duration.”
Self-citationPrimary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312100 · Cited by 286
Self-citationApoptosis and non-alcoholic fatty liver diseases
Kanda, T., Matsuoka, S., Yamazaki, M., Shibata, T., Nirei, K., Takahashi, H., Kaneko, T., Fujisawa, M., Higuchi, T., Nakamura, H., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i25.2661 · Cited by 270
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30246-7 · Cited by 191
Self-citationFarrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
Self-citationBoyer-Diaz, Z., Aristu-Zabalza, P., Andrés-Rozas, M., Robert, C., Ortega-Ribera, M., Fernández-Iglesias, A., Broqua, P., Junien, J.-L., Wettstein, G., Bosch, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.045 · Cited by 168
Adipose tissue hyperplasia and hypertrophy in common and syndromic obesity-the case of BBS obesity
Horwitz, A., & Birk, R. (2023) · Nutrients · doi:10.3390/nu15153445 · Cited by 143
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
“Seladelpar reduces the number of macrophages, fibrosis and other markers of stellate cell activity in a mouse model [177].”
BackgroundBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000395 · Cited by 127
“[18] Activation of PPARδ also induces antiinflammatory effects in macrophages, including Kupffer cells,[40] as confirmed in a study showing that seladelpar reduced macrophage numbers, fibrosis, and other markers of stellate cell activity in a mouse model.[41] A limitation of this study is its short duration due to ear…”
BackgroundSelf-citationMayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17755 · Cited by 39
Self-citationMechanisms of liver fibrosis in metabolic syndrome
Mehal, W. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100015 · Cited by 28
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis
Caines, A., Trudeau, S., & Gordon, S. C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2390120 · Cited by 7
“In mouse models, seladelpar normalized serum lipids and hepatic levels of free cholesterol and other lipotoxic lipids in obese, dyslipi-demic, and diabetic mouse models leading to a substantial decrease in steatosis and liver fibrosis [36].”
Advancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5
“It exerts anti-inflammatory, anti-fibrotic, and anti-cholestatic effects and is capable of reducing steatosis (in contrast to activation of PPAR γ, which enhances it) [53–56].”
Metadata
- Authors
- Haczeyni, F., Wang, H., Barn, V., Mridha, A. R., Yeh, M. M., Haigh, W. G., Ioannou, G. N., Choi, Y., McWherter, C. A., Teoh, N. C. ‐., & Farrell, G. C.
- Venue
- Hepatology Communications
- Published
- 2017-07-31
- Volume
- 1
- Issue
- 7
- Pages
- 663-674
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2741416895
- Cited by
- 101
- References
- 11
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.